This episode features David Stamler, Managing Director and CEO of Alterity Therapeutics (ASX:ATH), discussing the company’s progress in developing ATH434 as a potential treatment for Multiple System Atrophy (MSA), including Phase 2 clinical results, regulatory progress and preparation for a potential Phase 3 clinical trial. The conversation explores the significance of MSA as a rare neurodegenerative disease, ATH434’s clinical development pathway, recent findings and feedback, Phase 3 trial design, patient enrolment plans, timelines, funding considerations and the key milestones investors can expect as Alterity advances its clinical program.